Skip to main content
. 2019 Mar 5;16:17. doi: 10.1186/s12986-019-0344-9

Fig. 7.

Fig. 7

Effects of PPARγ agonist and antagonist on chemerin level in the serums (a), livers (b) and gastrocnemius (c) of EDM rats. PPARγ antagonist GW9662 had no influence on exercise-induced decrease of chemerin in serum (a) but significant reversed the decreases of chemerin in the livers (b) and gastrocnemius (c) of EDM rats at mRNA (upper) and protein (middle) levels. Pioglitazone further strengthened the down-regulations of chemerin in the serums (a), livers (b) and gastrocnemius (c) of EDM rats. The blots of chemerin were quantified by Tanon software and normalized against β-actin or GAPDH, then the normalized numbers were compared between different groups (bottom). DM: diabetes mellitus; EDM: exercised DM; EDP: EDM + pioglitazone; EDG:EDM + GW9662. *P<0.05, **P<0.01 vs DM. #P<0.05, ##P<0.01 vs EDM